Epirubicin

Generic Name: Epirubicin

Brand Names: Ellence, Pharmorubicin PFS

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 56420-45-2

Unique Ingredient Identifier: 3Z8479ZZ5X

Background: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

Indication: For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Associated Conditions: Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder

Associated Therapies: -

Clinical Trials

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 90

Registration Number: NCT00193024

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Epirubicin
Drug: Albumin-bound Paclitaxel

First Posted Date: 2005-09-19

Last Posted Date: 2021-11-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 123

Registration Number: NCT00193206

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 10 locations

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Epirubicin
Drug: Docetaxel

First Posted Date: 2005-09-19

Last Posted Date: 2021-10-26

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 110

Registration Number: NCT00193050

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: epirubicin
Drug: vinorelbine

First Posted Date: 2005-09-15

Last Posted Date: 2017-03-23

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 31

Registration Number: NCT00176488

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2005-09-13

Last Posted Date: 2008-07-18

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 338

Registration Number: NCT00162812

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-09-12

Last Posted Date: 2008-08-04

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 86

Registration Number: NCT00154739

Locations: 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2015-03-24

Lead Sponsor: Craig A. Bunnell, MD, MPH

Target Recruit Count: 55

Registration Number: NCT00146588

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Phase 1

Terminated

Conditions: Esophageal Cancer
Gastric Cancer
Tumors

First Posted Date: 2005-08-17

Last Posted Date: 2016-02-15

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 50

Registration Number: NCT00130936

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorouracil
Drug: paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-06

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1289

Registration Number: NCT00129922

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain

and more 61 locations

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Epirubicin
Drug: Capecitabine
Drug: Cyclophosphamide

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1384

Registration Number: NCT00129935

Locations: 🇪🇸
Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital General Universitario de Elda, Elda, Alicante, Spain

and more 55 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy